News & Updates
Showing Respirology articles
Showing

Smell, taste dysfunction post-COVID-19: will these persist?
Olfactory and gustatory** loss/alterations are common COVID-19 symptoms, but recovery is expected in most patients within the first 3 months. However, these dysfunctions may persist in some individuals, according to a reconstructed meta-analysis from Singapore.

Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.

Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.

Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
The use of metformin, fluvoxamine, or ivermectin in an outpatient setting did not appear to prevent progression to severe COVID-19, according to results of the phase III COVID-OUT trial.




